A Plunge of Nearly Half Its Value
ArriVent, a New York-listed company, acquired exclusive rights in 2021 to develop and commercialise firmonertinib outside China, becoming one of the earliest US biotech firms to license Chinese drug assets. According to the company, the phase 3 trial failed to show that the drug significantly slowed disease progression compared with standard chemotherapy.
"The results are not what we hoped for." — Bing Yao
ArriVent chairman and CEO Bing Yao called the results "disappointing" and said the company was evaluating the full trial dataset to determine the most appropriate development path for the drug. The market's reaction shows that for a company heavily reliant on a single lead product, one failed trial can wipe out nearly half its value in a single session.
Success in China Is Not a Ticket to the World
Tony Ren, head of Asia healthcare research at Macquarie Capital, said many out-licensed Chinese drugs are starting to face their "moments of truth" as they come under more rigorous scrutiny and higher global standards. He noted that firmonertinib was approved in China in February as a second-line treatment, while ArriVent's trial evaluated the drug as a first-line therapy for the same type of mutation.
















